Connor, Clark & Lunn Investment Management (CC&L)’s Oramed Pharmaceuticals ORMP Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$171K	Buy	50,207 +6,472	+15%	+$22K	﹤0.01%	1488
2025 Q4	$125K	Buy	43,735 +15,492	+55%	+$40K	﹤0.01%	1473
2025 Q3	$74.6K	Sell	28,243 -32,206	-53%	-$71.2K	﹤0.01%	1463
2025 Q2	$136K	Sell	60,449 -26,687	-31%	-$58.9K	﹤0.01%	1442
2025 Q1	$186K	Sell	87,136 -19,926	-19%	-$46K	﹤0.01%	1334
2024 Q4	$259K	Sell	107,062 -4,457	-4%	-$10.6K	﹤0.01%	1281
2024 Q3	$272K	Buy	+111,519	New	+$272K	﹤0.01%	1269
2022 Q1	–	Sell	-50,786	Closed	-$725K	–	1164
2021 Q4	$725K	Buy	50,786 +24,932	+96%	+$521K	﹤0.01%	727
2021 Q3	$568K	Buy	+25,854	New	+$440K	﹤0.01%	746

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Aquamarine Financial George Town $1.37B AUM

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

GIA

Gem Investment Advisors Teaneck, New Jersey $102M AUM

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ORMP Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Oramed Pharmaceuticals (ORMP) stake by 15% in Q1 2026, buying an estimated $22K and bringing the position to 50,207 shares worth $171K. The position accounts for ﹤0.01% of the portfolio, ranked #1488.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ORMP in Q3 2021 and has held it in 9 quarters since. The position peaked at $725K in Q4 2021. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 50,207 shares of Oramed Pharmaceuticals worth $171K as of Q1 2026.
Connor, Clark & Lunn Investment Management (CC&L) bought 6,472 Oramed Pharmaceuticals shares in Q1 2026, an estimated $22K.
Oramed Pharmaceuticals made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #1488 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Oramed Pharmaceuticals in Q3 2021 and has held it in 9 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Oramed Pharmaceuticals position peaked at $725K in Q4 2021.
64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.